In recent years, extensive attention has been given to the generation of new classes of ligand- specific binding proteins to supplement monoclonal antibodies. A combination of protein engineering and display technologies has been used to manipulate non-human antibodies for humanization and stabilization purposes or even the generation of new binding proteins. Engineered protein scaffolds can now be directed against therapeutic targets to treat cancer and immunological disorders. Although very few of these scaffolds have successfully passed clinical trials, their remarkable properties such as robust folding, high solubility, and small size motivate their employment as a tool for biology and applied science studies. Here, we have focused on the generation of new non-Ig binding proteins and single domain antibody manipulation, with a glimpse of their applications.

近年来，人们对新类别的配体特异性结合蛋白的产生给予了广泛的关注，以补充单克隆抗体。蛋白质工程和展示技术的组合已被用于操作非人类抗体，以实现人源化和稳定化目的，甚至产生新的结合蛋白。工程蛋白支架现在可以针对治疗靶点来治疗癌症和免疫疾病。尽管这些支架中很少有成功通过临床试验，但它们的显着特性，如坚固的折叠、高溶解度和小尺寸，促使它们被用作生物学和应用科学研究的工具。在这里，我们专注于产生新的非 Ig 结合蛋白和单域抗体操作，